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Abstract
Background: According to recent evidence, up to 40–50% of variance in autism spectrum disorder (ASD) liability
might be determined by environmental factors. In the present paper, we conducted a review of systematic reviews
and meta-analyses of environmental risk factors for ASD. We assessed each review for quality of evidence and
provided a brief overview of putative mechanisms of environmental risk factors for ASD.
Findings: Current evidence suggests that several environmental factors including vaccination, maternal smoking,
thimerosal exposure, and most likely assisted reproductive technologies are unrelated to risk of ASD. On the
contrary, advanced parental age is associated with higher risk of ASD. Birth complications that are associated with
trauma or ischemia and hypoxia have also shown strong links to ASD, whereas other pregnancy-related factors
such as maternal obesity, maternal diabetes, and caesarian section have shown a less strong (but significant)
association with risk of ASD. The reviews on nutritional elements have been inconclusive about the detrimental
effects of deficiency in folic acid and omega 3, but vitamin D seems to be deficient in patients with ASD. The
studies on toxic elements have been largely limited by their design, but there is enough evidence for the
association between some heavy metals (most important inorganic mercury and lead) and ASD that warrants
further investigation. Mechanisms of the association between environmental factors and ASD are debated but
might include non-causative association (including confounding), gene-related effect, oxidative stress, inflammation,
hypoxia/ischemia, endocrine disruption, neurotransmitter alterations, and interference with signaling pathways.
Conclusions: Compared to genetic studies of ASD, studies of environmental risk factors are in their infancy and
have significant methodological limitations. Future studies of ASD risk factors would benefit from a developmental
psychopathology approach, prospective design, precise exposure measurement, reliable timing of exposure in
relation to critical developmental periods and should take into account the dynamic interplay between gene and
environment by using genetically informed designs.
Keywords: Autism spectrum disorders, Environment, Epigenetics, Gene-environment interaction, Metals, Nutrition,
Pregnancy prenatal, Toxin, Vaccine
Background
Autism spectrum disorder (ASD) is a group of neurode-
velopmental disorders characterized by persistent im-
pairment in social communication and interaction and
restricted and repetitive patterns of behavior, interests,
or activities [1]. There is evidence that one in every 132
to one in every 68 individual suffers from ASD [2, 3].
According to a recent meta-analysis, ASD accounted for
7.7 million disability adjusted life years in 2010 and was
the leading mental cause of disability in children under
five in terms of years lived with disability [2].
While in the majority of cases of the exact etiology of
ASD remains unknown, novel technologies and large
population-based studies have provided new insight into
the risk architecture of ASD and the possible role of
environmental factors in etiology [4]. Twin studies pro-
vide a unique platform to study the relative contribution
of genetic and (shared and non-shared) environmental
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factors to the variability of a certain trait or disorder.
Dizygotic (DZ) twins on average share 50% of their
genes, and monozygotic (MZ) twins share 100% of their
genes. Twins are matched for many characteristics
including age, in utero and family environment, and
various aspects of early and late development. Taken to-
gether, these features allow for estimating heritability
(phenotypic variation that is attributable to the geno-
typic variation) of ASD by taking into the account its co-
variance within MZ and DZ twins [5]. Earlier twin
studies suggested heritability as high as 80–90% for ASD
with little contribution from the environment [4, 6, 7].
However, according to recent evidence, up to 40–50% of
variance in ASD liability is determined by environmental
factors [8–13]. Newer studies of monozygotic twins have
yielded concordance rates of <50%, with lower con-
cordance for dizygotic twins, suggesting that both
genes and environment play roles in the development
of ASD [4, 14–16]. Given the vulnerability of the de-
veloping brain to environmental factors, the causative
association between environmental factors and ASD is
biologically plausible [17]. Furthermore, historical proof-
of-concept evidence shows a causal relation between spe-
cific environmental risk factors such as thalidomide and
misoprostol and ASD [17–20].
In the present paper, we provide an evidence-based re-
view of the current knowledge about environmental risk
factors in ASD using findings from published systematic
reviews and meta-analyses. Although reviewing system-
atic reviews and meta-analyses inherently focuses on the
most well-studied findings, it automatically excludes the
studies that are published after the included reviews or
that, for any reason, are not systematically reviewed. It is
therefore important to keep in mind that the purpose of
this review is not to review all possible environmental
risk factors, but rather to provide a wide view of the evi-
dence landscape in epidemiology of risk factors for ASD.
Methods
We searched Pubmed since inception until December
2016 for ((autis*) or (“pervasive developmental disorder”)
or (“Asperger”)) and (“systematic review” or “meta-ana-
lysis”). We extracted the following for meta-analyses:
number of studies, study design, imprecision (>0.25 differ-
ence between effect estimates and their upper or lower
confidence bound for dichotomous variables and >0.5 dif-
ference for continuous outcomes), inconsistency (presence
of heterogeneity I2 > 50% or P value of heterogeneity test
< 0.10), magnitude of association (relative risk estimate
<2.0 small, 2.0–5.0 medium, >5.0 large), publication bias,
and indirectness (that is measuring exposure based on
population-level assessment) [21, 22]. Imprecision reflects
how wide or narrow the confidence interval is: the nar-
rower the confidence interval, the greater the precision.
Heterogeneity or inconsistency refers to the degree of
between-study variability in a meta-analysis.
A meta-analysis provides higher quality of evidence for an
association if it yielded precise, consistent, direct, and
strong association without publication bias. For systematic
reviews, we narratively summarized the authors’ conclusion
in a separate table (because quantitative assessment was not
possible). For each potential risk factor, the latest systematic
review or meta-analysis was considered unless indicated
otherwise (See Additional file 1: Table S1 for more details).
Results
A total of 663 citations were found. One additional
relevant reference was found through manual search of
the reference list in the remaining papers. Of these, 584
records were excluded by title or abstract. Of the remaining
80 studies, 32 references (9 qualitative systematic reviews
and 23 meta-analyses) were included for the purpose of the
review (See Additional file 1: Figure S1 and Table S1 for the
details on the excluded studies).
Figure 1 and Tables 1 and 2 summarize the findings of
meta-analyses and systematic reviews respectively. Below,
we present the evidence for nine different groups of risk
factors (including about 100 individual risk factors),
namely advanced parental age, pregnancy-related factors,
prenatal medication, maternal diseases, nutrition, environ-
mental toxins, vaccine, maternal smoking, and maternal
immigration.
Advanced parental age
Wu et al. [23] performed a meta-analysis of 27 studies on
association between advanced parental age and ASD. They
showed that every 10-year increase in maternal and pater-
nal age increases the risk of ASD in the offspring by 18
and 21% respectively. Furthermore, compared with the
reference age group, oldest age category (in both mothers
and fathers) was associated with a small but significant
and precise increase in risk of ASD in the offspring.
Pregnancy-related complications and conditions
Several systematic reviews and meta-analyses have sum-
marized the evidence on the association between preg-
nancy complications and ASD [24–27] (Tables 1 and 2).
Gardener et al. [24, 25] carried out two comprehensive
reviews of prenatal and perinatal risk factors for ASD.
They found statistically significant pooled estimates with
small effect size for abnormal presentation, breech presen-
tation, cord complications, fetal distress, multiple births,
low birth weight, small for gestational age, congenital
malformations, hyperbilirubinemia, and earlier birth (first
vs. third born). Evidence suggested a medium yet impre-
cise effect size for five risk factors including maternal
hemorrhage, Rh or ABO incompatibility, birth injury or
trauma, birth weight <1500 g, and feeding difficulties at
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birth. Large and imprecise effect sizes were observed for
neonatal anemia and meconium aspiration (Table 1).
A meta-analysis by our group has specifically addressed
the link between proxies of impaired gas exchange and
ASD [28]. Out of ten proxies that were analyzed, the effect
size was medium (and imprecise) for apnea/delayed cry-
ing, undefined hypoxia/asphyxia, 1-min Apgar score <6,
5-min Apgar score <8, and O2 treatment, and small and
imprecise for the rest (Table 1).
Curran et al. [29] reviewed 21 studies of the associ-
ation between cesarean section (C/S) and ASD. They
found a 36% increase in the risk of ASD following C/S
that was reduced after adjusting for confounders or lim-
iting the analysis to population-based studies and was
absent in the cohort studies. The effect size was small,
precise, and inconsistent. Moreover, they showed that
estimates were lower for elective C/S compared with
emergency C/S (Table 1).
In a systematic review of seven studies, Conde-Agudelo
and colleagues found that birth spacing <12 months and
>60 months are associated with a significantly increased
risk of ASD (Table 2) compared to the birth spacing in the
middle range. The estimates were of small magnitude,
inconsistent, and imprecise. However, the included
studies were generally of high quality. The estimates
were slightly larger for the former subtype autistic
disorder [30] (Table 1).
Xu and colleagues conducted a meta-analysis on the
association between maternal diabetes and ASD in the
offspring. For cohort studies, they found a 74 and 43%
(both small effect sizes) increase in risk for pregesta-
tional and gestational diabetes respectively (Table 1)
[31]. As expected, slightly higher odds ratios were ob-
served for case-control studies. In a meta-analysis of
seven studies, Wang and colleagues [32] showed that
overweight and obese mothers (but not underweight
mothers) have an increased risk of ASD by about 28 and
36% respectively. The increased risk for overweight
mothers was precise and consistent, whereas for obese
mothers, it was imprecise and inconsistent (Table 1).
Jiang et al. [33] systematically reviewed of maternal
infection during pregnancy and risk of ASD. Their most
important findings include a small but significant in-
crease in risk of ASD after maternal bacterial (18%) and
genitourinary infection (9%). The risk was precise but in-
consistent. They also found a small increase in ASD
after maternal flu that was precise, inconsistent, and
marginally significant.
A meta-analysis of ten studies by Chen et al. [34]
found that maternal autoimmune disease is associated
with a small but significant, precise, and consistent
increase in risk of ASD in the offspring. Similarly, a
meta-analysis of 11 studies by Wu et al. [35] showed that
family history of autoimmune illness increased the risk
of ASD. The effect size was small and inconsistent but
precise. In subgroup analysis, family history of auto-
immune thyroid disease, diabetes, psoriasis, and rheuma-
toid arthritis were associated with an average 49–64%
increase in risk of ASD in the offspring (Table 1).
Conti et al. [36] conducted a systematic review of the
association between assisted reproductive technology
(ART) and risk of ASD. Three out of seven studies sug-
gested an association between ART and ASD, but these
studies were of low quality. On the other hand, high-
quality studies showed no association between ART and
risk of ASD (Table 2).
Medication use during pregnancy
Gentile [37] systematically reviewed the evidence for the
association between maternal valproate use (a medication
Fig. 1 The association between several environmental factors and autism spectrum disorders; C/S, caesarian section; GDM, gestational diabetes
mellitus; HDoP, hypertensive disease of pregnancy; PROM, premature rupture of membrane; SSRI, selective serotonin reuptake inhibitor
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Table 1 Summary of meta-analyses of environmental risk factors for autism spectrum disorders
Risk factor [ref], year No. of
studies
Study design Estimates Precision Consistency Directness Publication
bias
Advanced parental age [23], 2017
• Highest paternal age category 20 4 cohort; 16 case-control + + − + Absent
• Highest maternal age category 19 4 cohort; 15 case-control + + − + Absent
Labor [25], 2011
• Prolonged labor 9 NA +/− − − + Absent
• Induced or augmented labor 8 NA +/− − − + Absent
• Precipitous labor 5 NA +/− − − + Absent
• Premature rupture of membranes 7 NA +/− − + + Absent
Delivery options [25], 2011
• Cesarean section [29], 2015 21 6 Cohort; 15 case-control + + − + Absent
• Emergency cesarean 4 NA +/− − − + Absent
• Elective cesarean 2 NA +/− − − + Absent
• Delivery anesthesia 7 NA +/− − + + Absent
• General anesthesia 3 NA +/− − + + Absent
• Assisted vaginal delivery 14 NA +/− + + + Absent
• Forceps 7 NA +/− − + + Absent
• Vacuum extraction 2 NA −/+ − − + Absent
Conditions at birth [25], 2011
• Abnormal presentation 15 NA + − − + Absent
• Breech presentation 4 NA + − + + Absent
• Cord complications 14 NA + − + + Absent
• Fetal distress 4 NA + − + + Absent
• Birth injury or trauma 6 NA ++ − + + Absent
• Twins or multiple birth 10 NA + − − + Absent
Maternal hemorrhage [25], 2011 4 NA ++ − + + Absent
Timing of birth [25], 2011
• January through March 4 NA +/− + + + Absent
• April through June 4 NA +/− − − + Absent
• July through September 4 NA +/− + + + Absent
• October through December 4 NA −/+ − − + Absentb
• Fall 3 NA −/+ − − + Absent
• Winter 3 NA −/+ − − + Absent
• Spring 3 NA −/+ − − + Absent
• Summer 3 NA + + + + Absent
Birth spacing (ref ≥36 m) [30], 2016 7 3 cohort; 3 cross-sectional;
1 case-control
• <12 months 5 NA + − − + NC
• 12–23 months 5 NA +/− − − + NC
• 24–35 months 5 NA −/+ − − + NC
Birth spacing (ref 24–59 m) [30], 2016
• <12 months 4 NA + − − − NC
• 12–23 months 4 NA + − − − NC
• >60 months 4 NA + − − − NC
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Table 1 Summary of meta-analyses of environmental risk factors for autism spectrum disorders (Continued)
Gestational age [25], 2011
• Postterm 14 NA +/− − − + Absent
• Preterm 17 NA +/− − − + Absent
• >4 weeks preterm 2 NA +/− − + + Absent
Birth weight [25], 2011
• Birth weight <2500 g 15 NA + − − + Absent
• Birth weight <2000 g 2 NA +/− − − + Absent
• Birth weight <1500 g 3 NA ++ − + + Absent
• Birth weight >4000 g 6 NA +/− − + + Absentb
Neonatal clinical and medical
conditions [25], 2011
• Meconium aspirated 3 NA +++ − + + Absentb
• Neonatal infection 2 NA −/+ − + + Absent
• Elevated temperature 2 NA +/− − − + Absent
• ABO or Rh incompatible 5 NA ++ − + + Absent
• Hyperbilirubinemia or jaundice 14 NA +/− − − + Absent
• Jaundice 4 NA +/− − + + Absent
• Hyperbilirubinemia 6 NA + − − + Absent
• Phototherapy 2 NA +/− − − + Absent
• Medical intervention in the first month 7 NA +/− − − + Absent
Impaired gas exchange [28], 2016
• Acidosis at birth 2 2 population-based + + + + Absent
• Apgar at 1 min <6 3 3 population-based ++ − + + Absent
• Apgar at 1 min <7 3 3 population-based + + + + Absent
• Apgar at 5 min <7 6 6 population-based + − + + Absent
• Apgar at 5 min <8 3 2 population-based; 1 clinic-based ++ − + + Absent
• Apgar at 5 min <9 2 1 population-based; 1 clinic-based +/− − + + Absent
• Apnea/delayed crying 5 3 population-based; 2 clinic-based ++ − − + Absent
• Respiratory distress 12 6 population-based; 6 clinic-based + + + + Absent
• Ventilation/O2 treatment 9 4 population-based; 5 clinic-based ++ − + + Presentc
• Undefined hypoxia/asphyxia 9 2 population-based; 7 clinic-based ++ − − + Absent
Mother born in another country
[24], 2009
5 NA +/− − − + Absent
Previous fetal loss [24], 2009 13 NA +/− − + + Absent
Birth order/parity [24], 2009
• 1 pregnancy increase 8 NA −/+ + − + Absent
• 1st vs. not 1st 11 NA +/− + − + Absent
• 1st vs. 2nd 4 NA +/− − − + Absent
• 1st vs. 2nd or 3rd 6 NA +/− − − + Absent
• 1st vs. 3rd+ 4 NA + + + + Absent
• 1st vs. 4th+ 6 NA −/+ − − + Absent
• 1st or 4th vs. 2nd or 3rd 5 NA +/− − − + Absent
• 4th vs. 2nd or 3rd 5 NA +/− − + + Absent
Maternal illness/conditions [24], 2009
• Maternal proteinuria 3 NA −/+ − + + Absent
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Table 1 Summary of meta-analyses of environmental risk factors for autism spectrum disorders (Continued)
• Toxemia/preeclampsia,
hypertension, swelling
25 NA +/− − − + Absent
• Maternal diabetes [31], 2014 12 3 cohort + + + + Absent
9 case-control + − + + Absent
• Maternal infection [33], 2016 15 2 cohort; 13 case-control + + − + Absent
• Bacterial infection [33], 2016 4 NA + + − + Absent
• Viral infection [33], 2016 4 NA +/− − − + Absent
• Influenza [33], 2016 3 NA +/ + − + Absent
• Genitourinary infection [33], 2016 8 NA + + + + Absent
• Skin infection [33], 2016 3 NA + − + + Absent
• Gastrointestinal infection [33], 2016 3 NA +/− − + + Absent
• Respiratory infection [33], 2016 7 NA +/− + + + Absent
• Family history of autoimmune
disease [35], 2015
11 3 cohort; 6 case-control; 2
cross-sectional
+ + − + Presentc
• Maternal autoimmune disease
[34], 2016
10 9 case-control; 1 cohort + + + + Absent
• Rubella 3 NA +/− − + + Absent
• Fever 4 NA +/− − + + Absent
• Nausea vomiting 6 NA +/− − − + Absent
• Physical injury accident 5 NA +/− − + + Absent
• Any illness 4 NA +/− − + + Absent
Maternal weight [32], 2016
• Maternal underweight 5 All cohort +/− + + + Absent
• Maternal overweight 5 All cohort + + + + Absent
• Maternal obesity 7 6 cohort; 1 case-control + − − + Absent
Prenatal visit [24], 2009 2 NA −/+ − − + Absent
Bleeding [24], 2009 19 NA + − − + Absent
• 1st trimester 2 NA +/− − + + Absent
• 2nd trimester 2 NA −/+ − + + Absent
• 3rd trimester 2 NA −/+ − + + Absent
Placental abnormalities [24], 2009 8 NA +/− − + + Absent
• Placenta previa 2 NA +/− − + + Absent
• Placenta abruption 2 NA −/+ − + + Absent
• Placental infarcts 2 NA +/− − + + Absent
High maternal weight gain during
pregnancy [24], 2009
5 NA −/+ − − + Absent
Maternal smoking [39], 2015 15 4 cohort; 11 case-control +/− + − + Absent
• Prenatal 8 NA +/− + − + NC
• Neonatal 2 NA − + + + NC
• Postnatal 5 NA + − − + NC
Medication use during pregnancy
[24], 2009
15 NA + − + +
• Anticonvulsants 2 NA +/− − + + Absent
• SSRIs [38], 2016 8 3 cohort; 5 case-control + − + + Absent
• Antidepressants [112], 2014 3 All case-control +/− − − + Absent
Thimerosal [47], 2014 9 1 retrospective and 2 prospective
cohort; 6 case-control
+/− + + Mixeda Presentd
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primarily used for epilepsy and bipolar disorder) and ASD
in the offspring. Studies with both prospective and retro-
spective design provided strong evidence for the associ-
ation of maternal valproate use and ASD as well as several
other neurodevelopmental outcomes. Valproate was asso-
ciated with poorer neurodevelopment than other antiepi-
leptic drugs. Furthermore, the association seemed to be
dose-related and robust to adjustment for several con-
founders including seizure attacks during pregnancy and
maternal intelligence quotient (Table 2).
The association between maternal antidepressant
use during pregnancy and ASD is more controversial.
Kobayashi et al. [38] quantitatively reviewed five case-
control and three cohort studies of maternal selective
serotonin reuptake inhibitor (SSRI) use in pregnancy
and the risk of ASD in the offspring. They found a
50% increase in risk of ASD of mothers who took
SSRIs during pregnancy; the estimate was imprecise
but consistent. However, when the authors conducted
a sensitivity analysis comparing SSRI-exposed group
Table 1 Summary of meta-analyses of environmental risk factors for autism spectrum disorders (Continued)
Inorganic mercury [47], 2014 3 3 case-control + − + + NC
Vaccination [52], 2014 10 5 cohort −/+ + + + Absent
5 case-control − + − + Absent
MMR vaccine [52], 2014 3 All cohort −/+ + + + Absent
Metal exposure [48], 2014
• Hg through vaccine [52], 2014 2 Both retrospective cohort +/−
• Hair Hg 7 All case-control +/− − NC + NC
• Hair Cd 4 All case-control −/+ − NC + NC
• Hair Pb 5 All case-control + − NC + NC
• Hair Cu 4 All case-control +/− − NC + NC
• Hair Se 3 All case-control −/+ − NC + NC
• Hair Li 3 All case-control −/+ − NC + NC
• Zn/Cu [113], 2015 11 All case-control −/+ − − + Absent
Nutritional intake [40], 2013
• Zinc [41], 2016 12 All case-control − + − + Absent
• Calcium 8 NA −− − − − Absent
• Carbohydrates 7 NA −/+ − − − Absent
• Energy 6 NA −/+ − − − Absent
• Fiber 6 NA +/− − − − Absent
• Iron 7 NA +/− − − − Absent
• Protein 7 NA −− − − − Absent
• Total fat 6 NA +/− − − − Absent
• Vitamin A 6 NA −/+ − − − Absent
• Vitamin C 7 NA −/+ − − − Absent
• Vitamin D [42], 2016 11 All case-control −−− − − + Possible
• Vitamin E 5 NA +/− − − − Absent
Air pollution [46], 2016
• PM10 (every 10 μg/m3) 6 5 case-control; 1 cohort + + − − NC
• PM2.5 (every 10 μg/m3) 3 3 case-control + + − − NC
• O3 (every 10 μg/m3) [114], 2014 2 2 case-control + + + − NC
+/−, positive but statistically non-significant effect estimates; +/, marginally positive; −/+, negative but statistically non-significant effect estimates; +, positive
statistically significant effect estimates (number of + corresponds to the strengths of the association); −, negative statistically significant effect estimates (number
of − corresponds to the strengths of the association)
aOnly direct −/+
bBegg’s test was not significant; Egger’s test was significant
cAdjusted for bias +
dAdjusted for bias −/+
NA not available, NC not calculated
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Table 2 Summary of systematic reviews of environmental risk factors for autism spectrum disorders
Risk factors Design Summary of findings Comments
Maternal immigration
[53], 2015
10 population-based The adjusted results showed higher rates
of ASD if children had migrant mothers
(2.69%) compared with children of
non-migrant mothers (0.91%). Six out of ten
studies found that giving birth postmaternal
migration significantly raised risks of ASD,
with the exception of children born to
Hispanic migrant mothers who had lower
rates of ASD (compared to all other migrant
groups)




3 case-control All studies showed an increased rate of ASD
in children whose parents were exposed to
chemicals
The studies were limited by







All showed an increased rate of ASD in children
with gestational exposure to chemicals including
two prospective studies of organophosphates
The studies provide enough evidence






1 prospective cohort; 1
computer model
One study showed an association between
organophosphate exposure; one between
DDE exposure and ASD, and one between
phosphine exposure and ASD
Air pollution during
prenatal period [49], 2014
6 retrospective All studies showed an increased rate of ASD
associated with air pollution (with particulate
matter in three studies and with NO2 in two
studies)
A meta-analysis of four prospective
European cohorts showed no




3 retrospective case-control All studies showed some association between
air pollution and ASD (association with NO2
is replicated in two studies)
Exposure to other
chemicals [49], 2014
2 prospective cohort; 4
retrospective case-control
No effect in prospective studies; retrospective




Toxic waste sites [49],
2014




2 ecological No association between water chlorination
and ASD in either studies
Heavy metals [49], 2014 8 ecological 7 studies showed association between Hg
and ASD, one showed no association
Ecological studies are limited by
indirect measures of exposure
In-house flooring [49],
2014
1 cohort Polyvinyl chloride vs. wood floor increases
the risk of ASD
Mercury levels [49], 2014 29 case-control 12 studies with elevation in at least one
tissue in patients with ASD
Studies measuring levels of heavy
metals were limited by cross-sectional
design and small sample size.
Furthermore, it is unclear how much
cross-sectional measurements of
metals in the body reflect the causal
effect of such exposures on ASD risk.
Lead levels [49], 2014 25 case-control 11 studies with elevation in at least one
tissue in patients with ASD
Cadmium levels [49],
2014
14 case-control 5 studies with elevation in at least one
tissue in patients with ASD
Aluminum levels [49],
2014
11 case-control 3 studies with elevation in at least one
tissue in patients with ASD
Arsenic [49], 2014 8 case-control 5 studies with elevation in at least one
tissue in patients with ASD
Nickel [49], 2014 3 case-control 2 studies with elevation in at least one
tissue in patients with ASD
Uranium levels [49], 2014 2 case-control 1 studies with elevation in at least one
tissue in patients with ASD
Tin levels [49], 2014 1 case-control 1 studies with elevation in at least one
tissue in patients with ASD
Heavy metals and
severity [49], 2014
7 correlational studies All studies showed some correlation
between ASD severity and heavy metal
levels (particularly Hg and Pb)
These studies suggest a dose-response
relationship between metal exposure
and ASD.
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to SSRI-non-exposed group in mother with psychi-
atric conditions, they found no significant increase in
risk of ASD in the offspring. Based on this evidence,
the authors concluded that the relation between SSRI
and ASD finding is largely due to confounding by
indication (Tables 1 and 2).
Maternal smoking
A meta-analysis of 15 studies by Rosen et al. [39]
found precise (but inconsistent) evidence that there
was no association between maternal smoking and
risk of ASD in the offspring. The lack of association
was unaffected by adjustment for socioeconomic
status and parental psychiatric history and was con-
sistent in assessments carried out during pregnancy
and at birth. For postnatal assessment of prenatal
smoking, there was a slight and imprecise increase in
risk, which might reflect a recall bias (Table 1).
Nutritional factors
Several studies have tried to establish an association be-
tween nutritional elements such as folic acid or vitamin
D and risk for ASD. However, many of those studies are
fundamentally limited by the fact that they have assessed
the deficiency and/or the efficacy of supplementing these
nutrients after developing ASD. Therefore, one should
be very cautious about causal interpretation of the find-
ings in those studies.
A meta-analysis by Sharp et al. [40] showed signifi-
cantly lower protein and calcium intake in children with
ASD. However, the estimates were imprecise, inconsist-
ent, and indirect. Another meta-analysis of 12 studies by
Babaknejad et al. [41] showed significantly lower zinc
levels in children with ASD. Wang et al. [42] performed
a meta-analysis of 11 studies of the association between
vitamin D and ASD. They found significantly lower
levels of serum 25-hydroxy vitamin D in subjects with
ASD than those in controls (Table 2). The pooled effect
Table 2 Summary of systematic reviews of environmental risk factors for autism spectrum disorders (Continued)
Heavy metals and
chelation [49], 2014
12 uncontrolled studies All showed improvement in symptoms
of ASD following chelation treatment




4 case-series; 7 case-control All studies showed some association
with severity, prediction, or oxidative stress




2 case series; 2 case-control Case series showed levels above normal
adult range for children with ASD; case-control
studies showed no association between
PCB and ASD
The studies were limited by either
lack of proper control group or small
sample size
Phthalate [51], 2016 2 cohort; 3 case-control Three studies showed association between
phthalate exposure and ASD; two studies
showed no association
PBDE [49], 2014 1 case-control PBDE resulted in higher activation of immune
response in patients with ASD
Valproate [37], 2014 1 population-based
prospective; 2 prospective
case series; 1 retrospective
All studies found significant and strong
association between prenatal valproate
exposure and ASD
The association between valproate
and ASD is likely to be causal given
the strength of association and
evidence for biological plausibility
Folic acid [44], 2016 11 studies The findings were inconsistent; some studies
provide support for the beneficial effect of
folic acid on risk of ASD, whereas others
show the opposite effect
Observational studies were limited
by self-report, whereas RCTs were
limited by use of multivitamin
Camel milk [115], 2016 2 small short-term RCTs Results showed beneficial effects on ASD
symptoms
It is unclear whether this benefit is
clinical and whether it extends to
longer period of treatment
Casein and gluten-free
diet [116], 2014
16 studies Findings are inconsistent Studies with positive findings were
mostly of low quality
Omega-3 [43], 2011 2 RCTs Studies found no evidence for beneficial
effects of omega-3 on ASD symptoms
Assisted reproductive
technologies [36], 2013
2 cohort; 5 case-control 3 studies showed positive association between
ART and ASD, 3 studies showed no association,
and 1 study showed a negative association
between ART and ASD. The authors concluded
that at present, no evidence supports the
association between ART and ASD
There are several sources of heterogeneity
such as study design, exposure definition,
data source, and confounders.
ART assisted reproductive technology, ASD autism spectrum disorder, DDE dichlorodiphenyldichloroethylene, NO2 nitrogen dioxide, RCT randomized
controlled trial
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size was large, but inconsistent and imprecise. Of note,
the number of studies that investigated vitamin D levels
in maternal blood during pregnancy was too small to
allow for a meta-analysis.
Systematic reviews of the association between omega-
3 fatty acids and ASD have mainly focused on interven-
tional studies. In a Cochrane review, only two small
randomized trials met the eligibility criteria [43]. The
authors found no evidence of a beneficial effect of
omega-3 in patients with ASD (Table 2).
Castro et al. [44] systematically reviewed the evidence
for folic acid involvement in risk of ASD. The authors
found some evidence for the association between folate
deficiency and ASD and ASD-like traits. However, the
findings were inconsistent and were limited by the self-
report in the majority of studies (Table 2). Another
systematic review suggested that folate deficiency might
interact with certain polymorphism in the methylene
tetrahydrofolate reductase (MTHFR) gene to increase
risk of ASD [45].
There are reports of other dietary interventions such
as camel milk and casein and gluten-free diet in ASD,
but studies of such interventions have generally been
short term and of low quality.
Exposure to toxins
Studies of toxic exposure have been largely limited by
indirect and cross-sectional methods of exposure meas-
urement. Quantitative systematic reviews have been
performed on air pollution, thimerosal (ethylmercury),
inorganic mercury, and hair levels of heavy metals. In a
meta-analysis, Lam and colleagues [46] found a small
but significant and precise association between prenatal
exposure to particulate matters and risk of ASD. How-
ever, the risk was inconsistent across studies and the
exposure was measured via indirect methods (Tables 1
and 2). Of note, the risk was substantially larger for par-
ticulate matter <2.5 μm compared to those of <10 μm.
In a meta-analysis of nine studies, Yoshimasu et al.
[47] found precise and consistent evidence for lack of as-
sociation between childhood thimerosal exposure and
ASD. The lack of association was consistent in pooled
analysis of the adjusted estimates, studies of anti-RhD
antibody treatment, and studies of direct thimerosal ex-
posure. In a meta-analysis of three case-control studies,
the same authors reported a 60% increase in risk of ASD
following higher level of inorganic mercury exposure.
Based on their findings, the authors suggested that early
life exposure to mercury by vaccination did not increase
the risk of ASD, whereas exposure to inorganic mercury
in the environment might be associated with an in-
creased risk of ASD (Table 1).
De Palma and colleagues [48] performed a meta-
analysis of studies that compared hair concentration of
heavy metals between patients with ASD and controls.
Their meta-analyses found little evidence for an associ-
ation between hair metal concentration of mercury,
copper, cadmium, selenium, and chromium. They did
find significantly higher levels of lead in the hair of
patients with ASD than those of controls. However, the
estimates for lead were imprecise and inconsistent
across studies and were disproportionately affected by
an outlier study (Table 1).
Rossignol et al. [49] carried out the most comprehen-
sive systematic review of environmental toxins in ASD.
The authors evaluated two groups of studies based on
direct or indirect assessment of exposure. Studies with
indirect assessment of exposure were generally of eco-
logical or retrospective nature and overall provide lower
grade of evidence as compared with studies of more dir-
ect exposure. Most of studies of indirect exposure have
shown an association between one or more environmen-
tal toxin exposures and ASD, even though the results
have been inconsistent. The most consistent finding
among this group of studies was for an association be-
tween environmental mercury exposure and ASD in
seven of eight ecological studies (Table 2).
Rossignol and colleagues [49] also made an exhaustive
effort of synthesizing the evidence on the relationship
between direct biomarkers of toxic exposure and ASD.
Systematic review of five metals (mercury, lead, cad-
mium, aluminum, and arsenic) contained eight or more
case-control studies. Studies measured metal concentra-
tions in blood, hair, tooth, urine, or brain. For all metals
but arsenic, more than half of studies showed no eleva-
tion in any of the measurement in patients with ASD
compared with control subjects. The authors further
identified seven studies that reported an association be-
tween heavy metal concentration (mostly mercury and
lead) and severity of ASD. Furthermore, 12 studies de-
scribed improvement in symptoms of ASD following
chelation therapy. However, none of these studies used a
placebo arm and are therefore difficult to interpret.
Importantly, a recent Cochrane systematic review found
no evidence for the beneficial effect of chelation therapy
on ASD [50] (Table 2).
Studies of the association between endocrine-disrupting
chemicals and ASD are scarce. Rossignol et al. [49]
reviewed two case-control studies of polychlorinated
biphenyls (PCB) and found no association between PCB
and risk of ASD, whereas Jeddi et al. [51] found that three
out of five studies of phthalate exposure showed a signifi-
cant association between phthalate exposure and risk of
ASD (Table 2).
Vaccination
Taylor et al. [52] performed a meta-analysis of studies that
investigated the association between childhood vaccines
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and ASD. The authors found no evidence for a higher risk
of ASD in subjects who are vaccinated. Their results were
precise, consistent (except for case-control studies), and
robust to study design or subtypes of ASD. Indeed, their
findings were suggestive of a protective effect of vaccines
on risk of childhood autism in case-control studies. Given
the concerns over the association between ASD and
the mumps, measles, and rubella (MMR) vaccine, the
authors conducted a separate meta-analysis of three
studies of MMR vaccine and ASD and found a non-
significant decrease in risk of ASD following MMR
vaccination (Table 1).
Maternal immigration
In a meta-analysis of five studies, Gardener et al. [24]
found imprecise and inconsistent association between
maternal immigration and ASD. Restricting the studies
to Nordic countries, they found a significant small effect
size for the association between immigration and ASD.
In a systematic review of the association between mater-
nal immigration and risk of ASD, Crafa and Varfa [53]
found ten eligible studies. The authors observed signifi-
cantly higher risk of ASD in the immigrants in three
studies, whereas five studies showed no difference be-
tween immigrant and non-immigrant mothers, and two
studies showed significantly lower risk of ASD in immi-
grants than that in non-immigrants. After controlling
for the effects of different sample sizes and ethnic back-
grounds, the results showed higher rates of ASD in
children of immigrant mothers (2.69%) compared with
those in children of non-migrant mothers (0.91%). Six
out of ten studies found that giving birth postmaternal
migration significantly increased the risk of ASD, with
the exception of children born to Hispanic migrant
mothers who had lower rates of ASD (Tables 1 and 2).
Possible mechanisms behind the association between
environmental risk factors and ASD
A fundamental question about the association between
environmental risk factors and ASD is whether the asso-
ciation represents an underlying causality or not. Al-
though evidence in this area is still speculative, here, we
briefly review the possible mechanisms of involvement
of environmental factors in ASD. It should be empha-
sized that the mechanisms reviewed here are by no
means exhaustive. Furthermore, each environmental fac-
tor—if causal—might involve multiple mechanisms and
at different levels of etiological pathways to ASD.
Non-causal associations
A plausible explanation for many of the observed envir-
onmental effects of ASD might be that of confounding.
For example, the association between several obstetric
complications and ASD might be partially confounded
by parity, because parity is associated both with the ex-
posure (i.e., birth complications) and the outcome (i.e.,
ASD) [54]. Moreover, a substantial proportion of what
might be interpreted as causal effect of environment on
ASD risk might result from a gene-environment correl-
ation. For example, many genetic conditions that are as-
sociated with ASD might also be associated with birth
complications. These epiphenomena are observed with
higher frequency in children with ASD but are not ne-
cessarily causal [55]. Similarly, the association between
maternal SSRI use and ASD might be due to confound-
ing by indication. Given that ASD has a high comorbid-
ity rate with depression, such associations might reflect
a shared risk mechanism rather than causality [56].
Confounding by gene-environment correlation might
also account for the association between other risk fac-
tors such as maternal immigration and ASD. It has been
proposed that fathers with autistic traits are more likely
to marry immigrant women [57].
Genetic and epigenetic-related effects
In addition to gene-environment correlation, environ-
mental factors could interact with genetic components
on various levels. It has been suggested that some envir-
onmental factors such as certain toxins and vitamin D
deficiency increase the risk of gene mutation that in turn
can lead to an increased risk of ASD [58]. Recent
evidence shows that a specific polychlorinated biphenyl
congener, PCB-95, might modify the number of copy
number variations leading to deletion or duplications of
15q11-q13, a genetic cause of ASD [59]. Maternal obes-
ity modifies the expression of several important genes
(such as apolipoprotein D) that are critical to neurodeve-
lopment in utero [60].
Epigenetic mechanisms are biochemical modifications
of DNA or histones that affect gene expression without
changing the DNA sequence. Epigenetic mechanisms
are thought to be critical in the normal development of
the nervous system [61]. Some environmental risk fac-
tors of ASD might affect neurodevelopment through
epigenetic mechanisms. For example, valproate, a strong
risk factor for ASD, inhibits histone deacetylase and
interferes with folic acid metabolism [62, 63]. Both
mechanisms result in significant alterations in epigenetic
modifications. Folate deficiency in a background of
methylene tetrahydrofolate reductase (MTHFR) gene
polymorphism might impair methyl donation and subse-
quently lead to impaired epigenetic regulation [64].
Assisted reproductive technology and maternal stress
(due to immigration) have also been linked to epigenetic
alterations [65, 66], although the importance of such as-
sociation with respect to ASD is unknown.
Genetic mechanisms also serve to make the individ-
uals susceptible to the effect of certain environmental
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risk factors. For example, mutation of Mecp2 gene (the
cause of Rett syndrome) and a regulator of the epige-
nome in neurons causes social deficit in mice with
prenatal exposure to the organic pollutant polybromi-
nated diphenyl ethers (PBDE) [67]. Paraoxonase is an
enzyme that metabolizes organophosphate. In a system-
atic review, Rossignol et al. [49] reported four studies
with decreased PON1 activity and three out of five
studies showing a significant association between PON
polymorphism and ASD. Similarly, they observed an
association between polymorphism of glutathione-S
transferase (responsible for detoxification of xenobi-
otics and heavy metals) and ASD in three of four
studies [49].
Inflammation and oxidative stress
ASD is associated with altered immune status, increased
oxidative stress, and an active neuroinflammatory
process characterized by microglial activation in various
parts of the brain [68–71]. A meta-analysis has indicated
that concentrations of several pro-inflammatory cyto-
kines such as interleukin-6, interluekin-1, and interferon
gamma are increased in patients with ASD compared to
those in healthy controls [70]. It is possible that the as-
sociation of maternal autoimmune disease with risk of
ASD is partly mediated through the effect of maternal
inflammatory mediators and autoantibodies on fetal neu-
rodevelopment [72, 73].
Another meta-analysis has demonstrated an associ-
ation between ASD and altered metabolism of glutathi-
one, an antioxidant [68]. Some environmental factors
such as lead, mercury, persistent organic pollutants, or
perinatal complications might cause a pro-inflammatory
state and oxidative damage in the brain and subse-
quently lead to alterations in neural growth and develop-
ment [69, 74–76]. Moreover, chemicals like brominated
flame retardants might result in mitochondrial toxicity
through a variety of mechanisms (including oxidative
stress) leading to impaired energy balance in the brain
[77]. Mitochondrial dysfunction has been documented
in patients with ASD [78].
Deth et al. [79] has made a case for a redox/methyla-
tion hypothesis of ASD. According to this hypothesis, in
a genetically sensitive individual, environmental toxins
(particularly toxic metals) cause significant oxidative
stress. This subsequently leads to impaired methylation
and alters the capacity for synchronizing neural net-
works through impaired dopamine D4 receptor func-
tion. Impaired methylation also affects epigenetic
mechanisms, leading to abnormal gene expression.
Both mechanisms (impaired synchronization of neural
networks and epigenetic alterations) are closely linked
to ASD [61, 62, 80–82].
Hypoxic-ischemic damage
Evidence shows that perinatal hypoxia and hypercarbia
are associated with various neurodevelopmental out-
comes including seizure, cerebral palsy, and intellectual
disability [83, 84]. As we mentioned earlier, evidence
suggests a role for birth asphyxia-hypoxia in risk for
ASD. Lack of oxygen and acidosis associated with hyper-
carbia alter cell energy metabolism and subsequently
lead to cell dysfunction and death [83]. Immaturity of
autoregulatory mechanisms and white matter suscepti-
bility in the neonate are important contributory factors
in hypoxic-ischemic brain damage [85]. Moreover, hyp-
oxic/ischemic insult induces inflammation, oxidative
damage, and excitotoxicity all of which can lead to
exacerbation of neuronal damage and death [85, 86].
Regions that are involved in cognitive function such as
hippocampus and cortex are commonly injured follow-
ing neonatal hypoxia [87]. A recent study has provided
insight into the possible mechanism of hypoxic damage
with regard to ASD [88]. The authors examined the role
of fragile X mental retardation protein (FMRP) and
mammalian target of rapamycin (mTOR) signaling path-
way in the pathogenesis of hypoxic-ischemic encephal-
opathy. Hereditary impairment of FMRP is seen in cases
of fragile X syndrome that is a well-recognized cause of
ASD. Importantly, the authors observed an overexpres-
sion of FMRP between 36 and 39 weeks of pregnancy in
the normal brain, which suggested an important physio-
logical role for FMRP in synaptic plasticity during this
period. Through comparing brain tissues of newborns
with hypoxic-ischemic encephalopathy (HIE) with healthy
controls, they found significantly lower FMRP expression
in the brain of HIE than healthy controls. Based on these
findings, the authors suggested that FMRP disruption
might be one of the mechanisms through which hypoxic-
ischemic damage is related to ASD.
Endocrine disruption
ASD affects gender differentially. Not only the preva-
lence of ASD seems to be higher in boys but also the
psychopathological, biochemical, and genetic aspects of
ASD also appear to be different between males and fe-
males [89, 90]. This gender difference has been attrib-
uted to a variety of factors, including diagnostic bias in
favor of males, extreme male brain (EMB) theory, and
female protective effect (FPE) [90, 91]. Out of all expla-
nations, EMB might be more related to the scope of our
review. EMB theory of ASD builds on an empathizing-
systematizing theory of psychological sex differences and
suggests that ASD might reflect an extreme male pattern
(i.e., more systematizing, less empathizing) [92]. It has
been suggested that the differential effect of testosterone
on sexually dimorphic brain regions might be a key
mechanism to push the brain beyond that of a typical
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male and toward an EMB. Therefore, factors that alter
hormonal balance (and particularly fetal testosterone)
might contribute to risk of ASD. An important class of
environmental factors that is capable of altering steroid
balance is endocrine-disrupting chemicals. For example,
brominated flame retardants are both associated with an
increased level of free testosterone and an increased risk
of ASD [93, 94]. Recent studies have shown that chemi-
cals (such as some PCB congeners) that are associated
with lower testosterone levels are also associated with
lower risk of autistic behaviors [93, 95].
Another link between endocrine disruptors and ASD
is alteration in thyroid function. Several studies have
shown evidence of prenatal maternal thyroid dysfunction
and ASD in the offspring [96, 97]. Interestingly, many
endocrine-disrupting chemicals that disrupt function of
thyroid hormone have also been hypothesized to in-
crease the risk of ASD [98–102].
Neurotransmitter alterations and abnormalities in
signaling pathways
Abnormalities in glutamate, serotonin, and gamma-
aminobutyric acid (GABA) have been linked to ASD
[103]. Although alterations in neurotransmitter pathways
can be the end result of many mechanisms we discussed
above, some environmental factors interact directly with
neurotransmitter pathways. For example, lead disrupts
the activity of N-methyl-D-aspartate (NMDA) receptors
on both pre- and postsynaptic levels [104]. Many
environmental pollutants have been associated with
altered glutamate levels in umbilical cord blood [105].
Similarly, it has been shown that brominated flame
retardants modulate GABA in the developing nervous
system [106].
Some environmental risk factors interact with intracel-
lular signaling pathways and might pave the way to im-
paired neurodevelopment. Exposure to PCB and PBDE
seems to alter calcium-related signaling pathway, leading
to alterations in dendritic growth and subsequent abnor-
malities in neuronal connectivity, a key feature of ASD
[106, 107]. Prostaglandin E2 (PGE2) is an important
regulatory element in calcium homeostasis and synaptic
plasticity in the developing brain [108, 109]. Evidence
suggests disruption of PGE2 as a possible mechanism
for the effect of organic chemicals, inflammation, and in-
fection on risk of ASD [109].
Limitations of current research
Compared to genetic studies of ASD, studies of environ-
mental risk factors are in their infancy. Many previous
studies of environmental risk factors have been limited
by small sample size, retrospective or cross-sectional
design, indirect measurement of exposure, and inability
to ascertain exact timing of exposure with relation to a
critical neurodevelopmental period. Moreover, for vari-
ous reasons, most previous studies have not investigated
important factors that might explain the heterogeneity
of ASD such as differences in risk between males and
females, differences between subtypes, and relation of
symptom severity to risk factors. Importantly, the defin-
ition of ASD is very broad and encompasses multiple
subtypes of the disorder, mirroring the etiological het-
erogeneity of the condition.
As results from large prospective cohorts or birth
registries are starting to emerge, more valuable data on
environmental risk factors become available. Still, het-
erogeneity of ASD, indirect measures, lack of a dimen-
sional approach, and diagnostic difficulties make it
challenging to draw substantial inferences from these
studies. As Mandy and Lai in their state in their recent
review, to understand the ASD, we must engage with its
complexity and take into the account the substantial het-
erogeneity of the factors that affect its onset as well as
its course [110]. Studies of environmental risk factors of
ASD can tackle this complexity by framing ASD as a de-
velopmental psychopathology or a maladaptive response
of the individual to its environment. This maladaptive
response is shaped by interplay between a multitude of
risk and protective factors at various levels and evolves
as the result of a dynamic interaction between a person
and their environment across the lifespan [110].
Furthermore, it is difficult to establish causality from
observational studies due to possibility of genetic and/or
environmental confounding. What is interpreted as an
environmental effect might indeed be an epiphenom-
enon due to gene-environment correlation. Therefore,
focus should be on designing studies that strengthen
causal inferences of environmental risk by ruling out al-
ternative explanation for the association. Studies that
use genetically informed approach (e.g., family-based
studies and in vitro fertilization designs) offer a new
way to address the challenge of gene-environment
correlation [111]. Moreover, gene-environment inter-
action and epigenetics of ASD are two areas that are
clearly understudied but, as recent evidence shows,
could potentially provide a substantial insight into the
etiology of ASD.
Conclusions
In the present paper, we reviewed systematic reviews
and meta-analyses of environmental risk factors for
ASD. Current evidence suggests that several environ-
mental factors including vaccination, maternal smoking,
thimerosal exposure, and most likely ART are unrelated
to risk of ASD. Birth complications that are associated
with trauma or ischemia and hypoxia have shown strong
links to ASD, whereas other pregnancy-related factors
such as maternal obesity, maternal diabetes, and C/S have
Modabbernia et al. Molecular Autism  (2017) 8:13 Page 13 of 16
shown a weak association with risk of ASD. Furthermore,
factors such as maternal use of SSRI or C/S might be indi-
cative of confounding by indication. The reviews on nutri-
tional elements have yielded limited useful and/
or inconclusive information about the beneficial effects of
folic acid and omega-3, while vitamin D deficiency seems
to be common in children with ASD. The studies on toxic
elements have been largely limited by their design, but
there is enough evidence for the association between some
heavy metals (most important inorganic mercury and
lead) and ASD that warrants further investigation. Reviews
on the psychosocial risk factors for ASD are scarce, with
maternal immigration being the only factor that has
shown some association with ASD in systematic reviews.
Biological underpinning of environmental risk factors of
ASD are debated but might include non-causative associ-
ation, gene-related effect, oxidative stress, inflammation,
hypoxia/ischemia, endocrine disruption, neurotransmitter
alterations, and interference with signaling pathways.
Future studies of ASD risk factors would benefit from a
developmental psychopathology approach, prospective de-
sign, precise exposure measurement, reliable timing of ex-
posure in relation to critical developmental periods
and should take into account the dynamic interplay be-
tween gene and environment by using genetically in-
formed designs.
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